Banner webinar 27 august 2020

COVID-19: What’s NMR got to do with it?

This webinar took place on August 27th 2020

Register to download slides & media

Overview

We are living through a public health crisis the likes of which has not been seen for generations. But we go into this crisis with one key advantage compared to previous generations - our scientific knowledge and capabilities are a major weapon against the virus, and we find ourselves in a race against time to develop effective therapies and preventative treatments. NMR is a key technique that forms a part of the backbone of analytical chemistry which so underpins much of drug discovery, development and manufacturing. This talk highlights the importance of NMR in this process, with particular reference to COVID-19. It focuses mainly on the impact of using NMR for the quality control and release of existing drug molecules which are in shortage for one reason or another due to the pandemic, and on the solutions which can assist in this process. The talk will be aimed at both spectroscopists and non-NMR experts alike.

Who should attend?

This webinar will be of interest to those looking to extend and improve their analytical capabilities, heads of analytical and chemical R&D, QC and manufacturing, laboratory managers and expert users of complementary technologies. It is especially dedicated to producers of APIs such as Remdesivir, Dexamethasone, Ribavirin, Midazolam, Hydroxychloroquine, Rocuronium Bromide and Azithromycin.

Speakers

Dr. Anna Codina
Dr. Anna Codina
Pharmaceutical Business Unit,Director, MRS Div.
Anna has a degree in Chemistry and a PhD in Protein NMR from the University of Barcelona, Spain. During this time, she did several industrial placements at pharmaceutical industries (Pharmhispania, Spain, and Genentech, SF, USA) and she worked for the NMR service of the University. She then moved to Cambridge, UK, to do a post-doc in protein NMR at the MRC Laboratory of Molecular Biology.

After her post-doc she worked in the Analytical R&D department of Pfizer, UK, for 8 years, becoming proficient in low level impurity structure elucidation, reaction monitoring, qNMR and the preparation of regulatory documentation.

She joined Bruker in 2011 as Material Characterisation Laboratory Manager. Since then her role has evolved. She started looking after the pharmaceutical market in 2015 as Product Portfolio Manager. She is now director of the pharmaceutical business Unit at Bruker BioSpin.
Dr. Gary Sharman
Dr. Gary Sharman
Senior Scientific Director
Gary recently joined Mestrelab after more than 20 years working in the Pharma industry, most recently for Eli Lilly where he spent 15 years in discovery chemistry at the Erl Wood site in the UK. He worked within the analytical chemistry group, specialising in NMR spectroscopy and the processing and management of data. Prior to that he worked in the NMR group at AstraZeneca, within the development chemistry group at Macclesfield UK. Gary studied for a PhD entitled “structure elucidation and molecular recognition in Secondary metabolites” with Professor Dudley Williams at the University of Cambridge, where he also completed his undergraduate degree in Natural Sciences.